伊托必利联合艾司奥美拉唑镁治疗食管运动功能障碍致胃食管反流病的临床观察-中国药房

伊托必利联合艾司奥美拉唑镁治疗食管运动功能障碍致胃食管反流病的临床观察

请在关注微信后，向客服人员索取文件

篇名：	伊托必利联合艾司奥美拉唑镁治疗食管运动功能障碍致胃食管反流病的临床观察
TITLE：
摘要：	目的：探讨伊托必利联合艾司奥美拉唑镁治疗食管运动功能障碍致胃食管反流病（GERD）的临床疗效。方法：选取我院2015年9月－2016年9月就诊的食管运动功能障碍致GERD患者100例作为研究对象，按照随机数字表法分为对照组和观察组，各50例。对照组患者给予艾司奥美拉唑镁肠溶片40 mg，po，qd；观察组患者在对照组基础上给予盐酸伊托必利片50 mg，po，tid。两组患者均连续治疗6周。观察两组患者临床疗效及治疗前后的症状积分、食管下括约肌（LES）静息压、液体/固体吞咽情况和食管体部蠕动压力，并记录不良反应发生情况。结果：观察组患者的总有效率达94.0％，显著高于对照组的78.0％，差异有统计学意义（P＜0.05）。治疗前，两组患者症状积分、LES静息压、液体/固体吞咽情况和食管体部蠕动压力比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者症状积分显著降低，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）；观察组患者LES静息压较治疗前显著升高，且显著高于对照组，差异均有统计学意义（P＜0.05）；两组患者液体吞咽成功率均显著增加，且观察组显著高于对照组，差异均有统计学意义（P＜0.05）；对照组患者固体吞咽成功率和液体/固体食管体部（近段、中段和远段）蠕动压力虽高于治疗前，但差异均无统计学意义（P＞0.05）；观察组患者固体吞咽成功率和液体/固体食管体部（近段、中段和远段）蠕动压力均显著高于治疗前，且显著高于对照组同期水平，差异均有统计学意义（P＜0.05）。两组患者治疗过程中均未见明显的不良反应发生。结论：伊托必利联合艾司奥美拉唑镁治疗食管运动功能障碍致GERD患者，能够显著改善其临床症状，有效提高食管LES静息压，增强食管体部运动功能，提高食管吞咽成功率，增强抗反流能力，且安全性较高。
ABSTRACT：	OBJECTIVE： To investigate the clinical efficacy of itopride combined with esomeprazole magnesium in the treatment of esophageal motility dysfunction-induced gastroesophageal reflux disease （GERD）. METHODS： A total of 100 patients with esophageal motility dysfunction-induced GERD were selected from our hospital during Sept. 2015-Sept. 2016， and then divided into control group and observation group according to random number table， with 50 cases in each group. Control group was given Esomeprazole magnesium enteric-coated tablets 40 mg， po， qd. Observation group was additionally given Itopride hydrochloride tablets 50 mg， po， tid， on the basis of control group. Both groups received treatment for consecutive 6 weeks. Clinical efficacies of 2 groups were observed， and symptom scores， LES resting pressure， liquid and solid swallowing and peristaltic pressure of esophageal body were observed before and after treatment. The occurrence of ADR was recorded. RESULTS： Total response rate of observation group was 94.0％， which was significantly higher than 78.0％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in symptom scores， LES resting pressure， liquid and solid swallowing or peristaltic pressure of esophageal body between 2 groups （P＞0.05）. After treatment， symptom scores of 2 groups were decreased significantly， and observation group was significantly lower than control group， with statistical significance （P＜0.05）. Compared with before treatment， LES resting pressure of observation group was increased significantly， and significantly higher than that of control group， with statistical significance （P＜0.05）. Success rate of liquid swallowing increased significantly in 2 groups， and that of observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. Success rate of solid swallowing， liquid and solid peristaltic pressure of esophageal body （near segment， middle segment and far segment） in control group were higher than before treatment， without statistical significance （P＞0.05）. Success rate of solid swallowing， liquid and solid peristaltic pressure of esophageal body （near segment， middle segment and far segment） in observation group were significantly higher than before treatment， and significantly higher than control group at corresponding period， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： For esophageal motility dysfunction-induced GERD， itopride combined with esomeprazole magnesium can significantly improve clinical symptom， effectively increase LES resting pressure， strengthen esophageal motor function， improve success rate of esophageal swallowing and enhance anti-gastroesophageal reflux ability with good safety.
期刊：	2017年第28卷第35期
作者：	张颖慧，李良平
AUTHORS：	ZHANG Yinghui，LI Liangping
关键字：	伊托必利；艾司奥美拉唑镁；食管运动功能障碍；胃食管反流病；食管下括约肌
KEYWORDS：	Itopride； Esomeprazole magnesium； Esophageal motor dysfunction； Gastroesophageal reflux disease； LES
阅读数：	673 次
本月下载数：	3 次

* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！